XML 64 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Omeclamox®-Pak, Ethyol®, Totect® and Methotrexate® - Narrative (Details) - USD ($)
shares in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 29, 2013
Nov. 30, 2016
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]            
Net product revenue       $ 40,376,563 $ 32,478,185 $ 33,013,184
Other revenue, potential upfront payment related to product sales       4,600,000    
Amended International Agreement | Pernix Therapeutics            
Business Acquisition [Line Items]            
Other revenue, potential upfront payment related to product sales $ 4,000,000          
Omeclamox-Pak            
Business Acquisition [Line Items]            
Additional upfront payments $ 4,000,000          
Net product revenue       1,800,000 2,500,000  
Omeclamox-Pak | Minimum            
Business Acquisition [Line Items]            
Royalty payments based on percentage over gross profits 15.00%          
Omeclamox-Pak | Maximum            
Business Acquisition [Line Items]            
Royalty payments based on percentage over gross profits 20.00%          
Ethyol | Minimum            
Business Acquisition [Line Items]            
Royalty payments based on percentage over gross profits 30.00%          
Ethyol | Maximum            
Business Acquisition [Line Items]            
Royalty payments based on percentage over gross profits 50.00%          
Methotrexate            
Business Acquisition [Line Items]            
Payments to acquire businesses   $ 100,000        
Liabilities incurred   $ 900,000        
Stock issued during period, acquisitions       1,300,000 1,000,000  
Omeclamox-Pak            
Business Acquisition [Line Items]            
Net product revenue       1,761,868 2,536,027 3,037,078
Product, Ethyol            
Business Acquisition [Line Items]            
Net product revenue       $ 10,835,038 $ 838,386 $ 0
Cardioxane            
Business Acquisition [Line Items]            
Net product revenue     $ 300,000      
Restricted Stock | Methotrexate            
Business Acquisition [Line Items]            
Stock issued during period, acquisitions (in shares)   180